CYCC Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 22:00):

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases...

Stats
Dagens volum	1.75M
Gjennomsnittsvolum	768 019
Markedsverdi	3.28M
EPS	$9.00 ( 2024-03-19 )
Neste inntjeningsdato	( $-5.92 ) 2024-05-09
Last Dividend	$0.150 ( 2016-07-13 )
Next Dividend	$0 ( N/A )
P/E	-0.0900
ATR14	$0.0320 (1.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-29	Schwartz Brian	Buy	12 500	Common Stock
2024-01-29	Schwartz Brian	Buy	12 500	Stock Option (right to buy)
2023-12-21	Mcbarron Paul	Buy	1 886	Common Stock
2023-12-21	Mcbarron Paul	Buy	1 886	Warrants (right to buy)
2023-12-21	Rombotis Spiro George	Buy	6 070	Common Stock

INSIDER POWER
100.00
Last 94 transactions
Buy: 3 599 901 \| Sell: 12

Volum Korrelasjon

Lang: -0.21 (neutral)

Kort: -0.13 (neutral)

Signal:(33.322) Neutral

Cyclacel Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
RMRM	0.961
INTZ	0.928
EAR	0.928
GMBL	0.926
JAGX	0.926
GNUS	0.925
VVOS	0.922
SMSI	0.921
UEIC	0.92
LVTX	0.919

10 Mest negative korrelasjoner
SGEN	-0.924
TIG	-0.89
LMRK	-0.885
APEN	-0.876
AGFS	-0.868
SERA	-0.868
AAON	-0.854
EPZM	-0.852
QADA	-0.85
TYHT	-0.848

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Cyclacel Pharmaceuticals Korrelasjon - Valuta/Råvare

0.10
( neutral )

0.29
( neutral )

0.00
( neutral )

0.16
( neutral )

0.63
( weak )

Cyclacel Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$420 000
Bruttogevinst:	$389 000 (92.62 %)
EPS:	$-26.51

FY	2023
Omsetning:	$420 000
Bruttogevinst:	$389 000 (92.62 %)
EPS:	$-26.51

FY	2022
Omsetning:	$0
Bruttogevinst:	$-32 000.00 (0.00 %)
EPS:	$-32.23

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-5.20

Financial Reports:

No articles found.

Cyclacel Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Cyclacel Pharmaceuticals Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.150	2016-07-13
Last Dividend	$0.150	2016-07-13
Next Dividend	$0	N/A
Payout Date	2016-08-01
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.150	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-03)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2016	$0.150	0.13%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-53.86	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-2.57	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-3.10	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	-0.00889	-1.000	-0.0889	0.0889	[0 - 1]
currentRatioTTM	0.912	0.800	-0.439	-0.351	[1 - 3]
quickRatioTTM	0.773	0.800	-0.157	-0.126	[0.8 - 2.5]
cashRatioTTM	0.414	1.500	8.81	10.00	[0.2 - 2]
debtRatioTTM	0.00420	-1.500	9.93	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-18.87	2.00	-6.29	-10.00	[0 - 30]
freeCashFlowPerShareTTM	-18.87	2.00	-9.44	-10.00	[0 - 20]
debtEquityRatioTTM	0.0610	-1.500	9.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.0580	1.000	-2.37	-2.37	[0.2 - 0.8]
operatingProfitMarginTTM	-61.55	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-435.46	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0477	0.800	-3.02	-2.41	[0.5 - 2]
Total Score				-4.75

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.100	1.000	-0.111	0	[1 - 100]
returnOnEquityTTM	-3.10	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-18.87	2.00	-6.29	-10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-18.87	2.00	-6.29	-10.00	[0 - 30]
payoutRatioTTM	-0.00889	1.500	-0.0889	0.0889	[0 - 1]
pegRatioTTM	-0.00287	1.500	-3.35	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-38.36	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-4.53

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.